Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Rev. Soc. Bras. Med. Trop ; 31(2): 221-224, mar.-abr. 1998. ilus
Article in Portuguese | LILACS | ID: lil-464103

ABSTRACT

Os autores relatam um caso de leishmaniose cutâneo-mucosa em uma paciente de 89 anos, diabética e hipertensa, tratada inicialmente com alopurinol por 10 meses não havendo cicatrização das lesões. Posteriormente, recebeu antimoniato de N-metil glucamina (glucantime) por 4 dias, na dose total de 2.380mg do Sbv, mas desenvolveu cardiotoxicidade e hipocalemia, sendo suspenso o tratamento, entretanto, evoluiu com regressão clínica total das lesões, apesar de ter recebido pequena dose desta medicação.


The authors report a case of a 89 years-old woman with mucocutaneous leishmaniasis and previous diabetes mellitus and high blood pressure, who had been treated with allopurinol for 10 months without healing of lesions. Afterwards, she has been treated with meglumine antimonate, [quot ]glucantime[quot ] for 4 days, with a total dose 2,380 mg of Sbv, but developed cardiac side effects and hypokalemia, hence the treatment was withdrawn. However, this patient developed total clinical regression of lesions, in spite of she has been received low dose of this drug.


Subject(s)
Aged , Aged, 80 and over , Female , Humans , Antiprotozoal Agents/administration & dosage , Organometallic Compounds/administration & dosage , Facial Dermatoses/drug therapy , Leishmaniasis, Mucocutaneous/drug therapy , Meglumine/administration & dosage , Facial Dermatoses/blood , Facial Dermatoses/parasitology , Leishmaniasis, Mucocutaneous/blood
2.
Rev. Soc. Bras. Med. Trop ; 30(6): 457-463, nov.-dez. 1997. tab, graf
Article in Portuguese | LILACS | ID: lil-464137

ABSTRACT

Foi avaliada a função renal de 11 pacientes com leishmaniose cutâneo-mucosa tratados com antimonial pentavalente na dose de 40mg SbV/kg/dia aplicada de 12/12 horas, em esquema contínuo, durante trinta dias. No estudo, um paciente apresentou insuficiência renal reversível e dois desenvolveram alterações enzimáticas hepáticas e eletrocardiográficas sendo o esquema terapêutico interrompido. Nos demais pacientes observou-se efeitos nefrotóxicos tais como diminuição da taxa de filtração glomerular, diminuição da capacidade de concentração urinária, avaliada por um jejum hídrico de 16 horas e aumento na fração de excreção de sódio. No exame do sedimento urinário observou-se um aumento no número de leucócitos e cilindros. Os resultados encontrados neste estudo sugerem que o tratamento com antimonial pentavalente na dose de 40mg SbV/kg/dia foi menos tolerado em virtude de seus efeitos tóxicos, não parecendo apresentar índice de cura superior ao esquema atualmente preconizado de 20mg SbV/kg/dia.


The renal function of eleven patients with mucocutaneous leishmaniasis was analyzed in a prospective study realized at the School Hospital of University of Brasília. The patients were treated with doses of 40 mg/kg/day of pentavalent antimony (Sb V), in a continuous scheme during thirty days. In this study three patients were excluded, one patient with reversible renal failure and two patients with hepatic and cardiac malfunctions. In the other eight patients, severe nephrotoxic effects were observed, like reduction of glomerular filtration rate, reduction of the urinary concentration capacity, evaluated by a sixteen hours hydric fasting and an increase of sodium fractional excretion. An increase in the number of leucocytes and cylinders were observed at the urinary sediment exam. Finally, the results shows that the treatment with pentavalent antimony in doses of 40 mg Sb/kg/day was less tolerated on account of its renal toxic effects. This scheme seems not be superior than the currently preconized scheme of 20 mg of Sb V/kg/day during 30 days.


Subject(s)
Adolescent , Adult , Animals , Humans , Middle Aged , Antimony/administration & dosage , Antimony/adverse effects , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/adverse effects , Organometallic Compounds/administration & dosage , Leishmania braziliensis , Leishmaniasis, Mucocutaneous/drug therapy , Meglumine/administration & dosage , Meglumine/adverse effects , Kidney/drug effects , Organometallic Compounds/adverse effects , Drug Evaluation , Drug Tolerance , Leishmaniasis, Mucocutaneous/physiopathology , Prospective Studies , Kidney/physiopathology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...